{"id":"NCT01810380","sponsor":"H. Lundbeck A/S","briefTitle":"Brexpiprazole in Patients With Acute Schizophrenia","officialTitle":"Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2013-03-13","resultsPosted":"2016-03-29","lastUpdate":"2017-03-16"},"enrollment":468,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Brexpiprazole","otherNames":[]},{"type":"DRUG","name":"Quetiapine extended release","otherNames":["Seroquel XL®/XR®"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Brexpiprazole","type":"EXPERIMENTAL"},{"label":"Quetiapine extended release","type":"OTHER"}],"summary":"To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.","primaryOutcome":{"measure":"Change From Baseline to Week 6 in PANSS Total Score","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Placebo","deltaMin":-15.9,"sd":1.5},{"arm":"Brexpiprazole","deltaMin":-20,"sd":1.5},{"arm":"Quetiapine Extended Release","deltaMin":-24,"sd":1.5}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0560"},{"comp":"OG000 vs OG002","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40859756","39749727","35235720","34901863"],"seeAlso":["https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002252-17/results"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":161},"commonTop":["Somnolence","Weight increased","Headache","Insomnia","Dizziness"]}}